

1 **Standard Blood Laboratory as a Clinical Support Tool to Distinguish between**
2 **SARS-CoV-2 Positive and Negative Patients**

3

4 Rainer Thell^{1,2,3}, M.D., Jascha Zimmermann⁴, Marton Szell^{1,2}, M.D., Sabine

5 Tomez, M.D., Philip Eisenburger^{1,4}, M.D., Moritz Haugk¹, M.D., Anna Kreil¹,

6 M.D., Alexander Spiel¹, M.D., Amelie Blaschke^{1,2}, M.D., Anna Klicpera^{1,2}, M.D.,

7 Oskar Janata^{1,2}, M.D., Walter Krugluger^{1,2}, M.D., Christian Sebesta^{1,2}, M.D.,

8 Harald Herkner³, M.D., and Brenda Laky^{3,5}, M.Sc., Ph.D.

9

10 ¹ Wiener Gesundheitsverbund (R.T, M. S., S.T., P.E., M.H., A.K., A.S., A.B., A.K., O.J., W.K.,
11 C.S.)

12 ² Department of Internal Medicine 2, Emergency Department, Klinik Donaustadt, Vienna,
13 Austria

14 ³ Medical University Vienna, Austria

15 ⁴ Sigmund Freud University, Medical School, Vienna, Austria

16 ⁵ Austrian Research Group for Regenerative and Orthopedic Medicine (AURROM), Vienna,
17 Austria

18

19 **Keywords.** COVID-19; SARS-CoV-2; standard blood laboratory

20 Running title Standard blood laboratory for diagnosis of COVID-19

21

22

23

24

25

26 Corresponding author:

27 Rainer Thell, MD

28 Department of Internal Medicine 2, Emergency Department, Klinik Donaustadt, Vienna,

29 Austria

30 Address: 122 Langobardenstrasse, 1210-Vienna, Austria

31 E-mail: rainer.thell@meduniwien.ac.at

32 Mobile: +43 676 8311 2550

33 Alternate corresponding author:

34 Brenda Laky, MSc, PhD

35 Medical University of Vienna, Austria

36 Austrian Research Group for Regenerative and Orthopedic Medicine (AURROM),

37 Vienna, Austria

38 Address: Hartmannngasse 15/10, 1050 Vienna, Austria

39 Mobile: +43 699 1068 2574

40 E-mails: brenda.laky@meduniwien.ac.at or brenda.laky@aurrom.org

41

42 **Summary**

43

44 Decreasing leucocytes and eosinophils and increasing hemoglobin and CRP were significantly
45 associated with an increased likelihood of being COVID-19 positive tested. Each single
46 parameter showed either a high sensitivity (leucocytes, eosinophils, CRP, monocytes,
47 thrombocytes) or specificity (NLR, CK, ALT, lipase), or a sensitivity and specificity around 60%
48 (Hb, LDH, AST).

49

50 **ABSTRACT**

51

52 **Background.** Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
53 syndrome coronavirus 2 (SARS-CoV-2) is current pandemic disease. Acute polymerase-chain-
54 reaction is the gold standard test for this disease, is not available everywhere. Standard blood
55 laboratory parameters may have diagnostic potential.

56 **Methods.** We evaluated standard blood laboratory parameters of 655 COVID-19 patients
57 suspected to be infected with SARS-CoV-2, who underwent PCR testing in one of five hospitals
58 in Vienna, Austria. Additionally, clinical characteristics and 28-day outcome were obtained from
59 medical records. We compared standard blood laboratory parameters, clinical characteristics, and
60 outcomes between positive and negative PCR-tested patients and evaluated the ability of those
61 parameters to distinguish between groups.

62 **Results.** Of the 590 study patients including 276 females and 314 males, aged between 20 and
63 100 years, 208 were tested positive by means of PCR. Patients with positive compared to
64 negative PCR-tests had significantly lower levels of leukocytes, basophils, eosinophils,
65 monocytes, and thrombocytes; while significantly higher levels were detected with hemoglobin,
66 C-reactive-protein (CRP), neutrophil-to-lymphocyte ratio (NLR), activated-partial-
67 thromboplastin-time (aPTT), creatine-kinase (CK), lactate-dehydrogenase (LDH), alanine-
68 aminotransferase (ALT), aspartate-aminotransferase (AST), and lipase. Our multivariate model
69 correctly classified 83.9% of cases with a sensitivity of 78.4%, specificity of 87.3%, positive
70 predictive value of 79.5%, and negative predictive value of 86.6%. Decreasing leucocytes and
71 eosinophils and increasing hemoglobin and CRP were significantly associated with an increased
72 likelihood of being COVID-19 positive tested.

73 **Conclusions.** Our findings suggest that especially leucocytes, eosinophils, hemoglobin, and
74 CRP are helpful to distinguish between COVID-19 positive and negative tested patients and that
75 a certain blood pattern is able to predict PCR-results.

76 INTRODUCTION

77

78 In December 2019, an uncommonly high incidence of pneumonia occurred in Wuhan province,
79 China, caused by a previously unknown pathogen and showing an unusually high mortality rate,
80 which showed to be a novel corona virus, SARS-CoV-2 (Severe Acute Respiratory Syndrome –
81 Corona Virus 2).[1] It causes coronavirus disease (COVID-19) which has reached pandemic
82 levels resulting in significant morbidity and mortality affecting all inhabited areas of the world
83 with large numbers of patients. Hence, the World Health Organisation (WHO) declared a
84 worldwide pandemic in March 2020.

85 Diagnostic steps for this disease currently are epidemiological contact history, clinical
86 impression, chest radiography, standard blood laboratory, and antigen detection by means of
87 real-time fluorescence PCR. PCR is the gold standard test for detection of SARS-CoV-2
88 infection.[2]

89 It soon became apparent that the available test capacities for PCR testing were far from
90 sufficient, and a feverish search for alternative and simpler detection methods began. To date,
91 point-of-care PCR testing is still not available everywhere. Testing that takes a long time can
92 make up for significant additional efforts of organisation of patient cohorts in hospitals.

93 The clinical appearance of the disease is broadly reported.[3] Signs and symptoms may include
94 fever and cough most commonly, dyspnea, rarely diarrhea, anosmia, or ageusia and others, at the
95 beginning or during the course of the disease.[4-6] Various publications indicated that COVID-
96 19 positive patients showed typical laboratory patterns,[7-9] although many of the earlier studies
97 report on relatively small numbers of COVID-19 positive patients.

98 Zhang et al. included 95 cases with COVID-19-positive pneumonia.[7] They found significantly
99 higher numbers of D-Dimer, C-reactive protein (CRP), and procalcitonin in patients to be
100 admitted to intensive care levels. In a retrospective report of 138 admitted patients, lymphopenia
101 occurred in 70%, a prolonged prothrombin time in 58%, and an elevated lactate dehydrogenase

102 (LDH) resulted in 40% of patients.[10] In an Iranian cohort of 70 COVID-19 positive patients,
103 Mardani et al. found significantly higher neutrophil count, CRP, LDH, aspartate
104 aminotransferase (AST), alanine aminotransferase (ALT), and urea levels, as well as lowered
105 white blood count and albumin levels.[11] A further retrospective trial of 99 patients showed
106 decreased lymphocyte counts in 35%, decreased albumin in 98%, increased LDH in 75%, an
107 increased interleukin-6 in 52%, and raised CRP in 86% of patients were reported.[3] Li et al.
108 performed a trial with 989 patients, detecting a combination of eosinopenia and elevated CRP
109 yielding a sensitivity of 67% and specificity of 78% for COVID-19.[12] In an additional cohort
110 of 458 patients from Guan et al., leukopenia, lymphopenia, eosinopenia, and an increased CRP
111 were detected.[4] In two trials, an increased NLR was described as an independent risk factor of
112 mortality for COVID-19 patients.[13, 14]

113 Standard blood laboratory data are potentially of both, diagnostic and prognostic value.[15] On
114 one hand, they can contribute to judge the pre-test probability of a COVID-19 diagnosis and
115 thus, support the effective and efficacious organisational management of a patient in an
116 emergency department. On the other hand, it is of potential value, if standard blood laboratory
117 blood results can help to distinguish a potentially life-threatening course of a disease from a less
118 critical status.

119 Therefore, the overall aim of this study was to evaluate standard blood laboratory parameters and
120 clinical characteristics in a large number of COVID-19 suspicious patients, who underwent PCR
121 testing. The specific aim was to determine whether standard blood laboratory parameters are able
122 to identify positive COVID-19 patients from a large COVID-19 suspected cohort.

123

124 **MATERIALS AND METHODS**

125 **Data Source**

126 Data were obtained from an electronical data base of the Vienna Health Care Association
127 (Wiener Gesundheitsverbund), which stores all medical records of patients treated in its hospitals

128 in Vienna, Austria. Data extraction was exclusively performed by authorised employees of the
129 emergency department at the Klinik Donaustadt, Vienna. The study protocol was approved both
130 by the Ethics Commission of the City of Vienna (EK 20-122-VK) and the Ethics Commission of
131 Sigmund Freud University Vienna (161/2020).

132

133 **Data Collection**

134 Data were collected from female and male adult patients with suspected COVID-19 who
135 underwent reverse transcriptase PCR testing via a nasopharyngeal swab performed at one of the
136 five hospitals (Klinik Donaustadt, Klinik Floridsdorf, Klinik Hietzing, Klinik Landstrasse, and
137 Klinik Ottakring) between February 27, 2020 and April 27, 2020. Based on PCR results, patients
138 were divided into a COVID-19 positive or negative group. Patients without reported standard
139 blood laboratory reports, medical history, or outcome documentation at day 28 after consultation
140 were not included.

141 As standard blood laboratory testing was performed according to the clinical care needs of the
142 patients, not all parameters were available for all patients. Parameters available from less than 20
143 patients in the positive or negative group were not analysed. Routine blood tests generally
144 included full blood count, blood chemistry, electrolytes, liver function parameters, renal and
145 myocardial function parameters as well as coagulation markers and markers of inflammation.

146 Patients' gender (female/male), age at time of PCR testing (years), coexisting diseases and
147 conditions (e.g. chronic diseases of the lung, liver, kidney; coronary artery disease, diabetes, and
148 arterial hypertension); the clinical 28-day outcome including hospital admission and discharge as
149 well as requirement of intensive care and ventilation, and death details were extracted from
150 medical records.

151

152 **Statistical Analysis**

153 Descriptive statistics was used to describe the characteristics of patients. The distribution of the
154 data was determined by visual inspection of the histograms and the Kolmogorov Smirnov tests.
155 Normally distributed data were calculated as mean value with standard deviation (SD), otherwise
156 as median and interquartile range (IQR).

157 Continuous variables were compared between COVID-19 positive and negative patients with
158 independent t-tests (parametric) or Mann-Whitney U-tests (non-parametric). Blood parameters
159 were categorised according to normal reference ranges used in hospitals. However, since CRP
160 ranges higher than normal (cut off: 0.5mg/dL) were detected in almost all patients (COVID-19
161 positive: 99.5% and negative: 98.2%) and thus, useless to discriminate between COVID-19
162 positive and negative patients, coordinates of the receiver operating characteristic (ROC) and the
163 Youden index were used to determine another, sensitivity and specificity balanced, cut off value
164 for CRP in our cohort. Chi-square or Fisher's exact tests were applied to describe the relationship
165 between proportions of categorical variables. Correlations between the continuous parameters
166 were performed using Kendall's Tau. Since neutrophils significantly correlated with leucocytes
167 (0.859; $p < 0.001$) and to reduce the number of predictive variables, we used the neutrophils-to-
168 lymphocytes ratio (NLR) instead of neutrophils and lymphocytes. A cut-off for NLR was
169 determined using coordinates of the ROC and the Youden index (sensitivity and specificity
170 balanced). Hemoglobin was used instead of erythrocytes (0.761; $p < 0.001$) and hematocrit (0.874;
171 $p < 0.001$) due to significant correlations. Procalcitonin and D-Dimer were also not included due
172 to the small sample size. For further analysis between COVID-19 positive and negative patients,
173 only significant different and clinical meaningful parameters were considered.

174 Univariate and multivariate binomial logistic regression analyses were used to construct
175 prediction models using PCR results (COVID-19 positive/negative) as the dependent variable
176 and significant patients' characteristics and blood parameters as predictors (independent
177 variables). Linearity of the continuous variables regarding the logit of the dependent variable

178 was assessed using Box-Tidwell procedure with Bonferroni correction. None of the continuous
179 variables violated the linearity assumption. None of the parameters showed multicollinearity.

180 Percentage accuracy in classification (PAC), sensitivity, specificity, positive predictive value
181 (PPV), and negative predictive value (NPV) were estimated to assess models' performance. Area
182 under the ROC curves (AUC) were determined in order to assess the overall discriminatory
183 ability of the model and of blood parameters to distinguish between COVID-19 positive and
184 negative patients. Statistical significance was set at a p-value of <0.05 (two-sided). All data were
185 analysed with SPSS software (IMP Statistics Version 25; SPSS Inc, Chicago, IL).

186

187 **RESULTS**

188 **Characteristics of COVID-19 Suspected Patients**

189 A total of 655 patients from the four hospitals underwent PCR testing between February 27,
190 2020 and April 27, 2020. Forty-five patients were not evaluated due to missing data. Another 17
191 patients who were tested within this time period with complete data sets were excluded since
192 they were hospitalized more than one month before (n=16) or more than seven days after (n=1)
193 PCR-testing. Patients (n=3) with both eosinophilia and acute malignant disease were excluded as
194 well.

195 The median age of the 276 female (46.8%) and 314 male (53.2%) patients was 71 years (range,
196 20-100years; 60.7% of the patients were ≥ 65 years of age at time of PCR testing). No
197 comorbidities were recorded in 69 (33.2%) and 84 (22.0%) COVID-19 positive and negative
198 tested patients, respectively. COVID-19 negative tested patients had significantly more
199 comorbidities than COVID-19 positive tested patients (median (IQR): 1 (1-3) vs. 1 (0-2); p
200 <0.001). The most common comorbidity was pre-existing arterial hypertension (58.1%),
201 followed by diabetes (25.4%), coronary heart disease (19.5%), chronic lung disease (16.9%),

202 chronic kidney disease (15.8%), malignant diseases (13.6%), cerebrovascular accidents (7.5%),
203 chronic liver disease (4.2%), and human immunodeficiency virus (HIV, 0.5%).

204 A comparison between demographic characteristics and comorbidities between COVID-19
205 positive and negative tested patients showed no significant differences between the groups
206 (Table 1).

207 Similar numbers of outpatients tested positive (11.1%) or negative (8.6%; $p=0.338$). There was
208 also no significant difference between COVID-19 positive compared to negative tested patients
209 regarding the number of patients requiring ICU and/or ventilation (4.0% vs. 9.3%, respectively;
210 $p=0.091$). Significantly more COVID-19 positive (25.5%) than negative (9.2%) tested patients
211 died before day 28 ($p<0.001$). Main causes of death in COVID-19-positive patients were, in
212 descending order, pneumonia (67.3%), followed by multi-organ failure (24.5%), acute cardiac
213 failure (7.6%), and acute renal failure (1.9%).

214

215 **Comparison of Standard Blood Laboratory Parameters between Covid-19 Positive and** 216 **Negative Patients**

217 COVID-19 positive patients had significantly lower levels of leukocytes, NLR, basophils,
218 eosinophils, monocytes, and thrombocytes; while significantly higher levels were detected with
219 hemoglobin, CRP, aPTT, CK, LDH, ALT, AST, and lipase compared to COVID-19 negative
220 patients. Similar levels were detected regarding procalcitonin, albumin, glucose, potassium, total
221 bilirubin, GGT, creatinine, and BUN between the groups (Supplement Table 1). Parameters with
222 significant differences are presented in Table 2.

223 After dichotomizing blood laboratory parameters, similar significances were detected (Table 2);
224 while binary comparisons of aPTT (normal+high (≥ 21 sec): 97.9% positive vs. 97.6% negative)
225 and total bilirubin (normal+high (≥ 0.3 mg/dL): 93.6% positive vs. 89.6% negative) showed no

226 significant differences between positive and negative tested patients ($p=0.885$ and $p=0.132$,
227 respectively).

228

229 **Univariate and Multivariate Analyses of Standard Blood Laboratory Parameters**

230 Univariate logistic regression analysis with COVID-19 positive tested patients as the dependent variable
231 revealed that the majority of blood parameters including the dichotomized levels were associated with a
232 positive COVID-19 diagnosis (Table 3). Comorbidities due to their low discrimination ability and
233 parameters without significant associations were not included in further multivariate analyses
234 (Supplement Table 2).

235 The multivariate logistic regression model was statistically significant (Chi-square (14) = 119.2; $p<0.001$)
236 and explained 62.8% (Nagelkerke R^2) of the variance in COVID-19 positive tested patients and correctly
237 classified 83.9% of cases. Sensitivity was 78.4%, specificity was 87.3%, positive predictive value was
238 79.5%, and negative predictive value was 86.6%. Of the 14 predictors, four were statistically significant
239 including leucocytes, eosinophils, hemoglobin, and CRP (Table 3). Decreasing leucocytes and
240 eosinophils as well as increasing hemoglobin and CRP were associated with an increased likelihood of
241 being COVID-19 positive tested. AUC, as a measure of the overall discriminatory ability of the model,
242 and the model's best blood parameters combined are presented as ROC curves in Figure 1.

243

244 **Diagnostic Performance of Single Standard Blood Laboratory Parameters**

245 Diagnostic performance of those four dichotomized blood parameters, which were significant at the
246 multivariate logistic regression as well as those, which were significant at the univariate analysis, were
247 evaluated regarding their ability as single parameter to distinguish between COVID-19 positive from
248 negative tested patients (Table 4). Each single parameter showed either a high sensitivity (leucocytes,
249 eosinophils, CRP, monocytes, platelets), a high specificity (NLR, CK, ALT, lipase), or a sensitivity and
250 specificity around 60% (hemoglobin, LDH, AST).

251

252 **DISCUSSION**

253 In this trial, we showed that the likelihood of a SARS-CoV-2 infection can be enforced through
254 standard laboratory blood findings to a high degree. Several studies including meta-analyses
255 recently focused on prediction of the severity of the disease derived from blood results.[8, 9, 16]
256 Our consideration to find a model to predict the diagnosis of SARS-CoV-2 infection with
257 standard blood parameters has been less studied.

258 To our knowledge, only three other trials comparing standard blood parameters between positive
259 and negative cases are published to date.[11, 12, 17] Similar to those studies, our study showed
260 that leucopenia, eosinopenia, elevated hemoglobin, and CRP were detected to be among the best
261 standard laboratory parameters to distinguish between COVID-19 positive from negative tested
262 patients. Accordingly, similar patterns have been detected in positive COVID-19 patients with a
263 severe compared to a mild form of the disease.[8, 9, 16] The major differences of the three
264 studies, which compared COVID-19 positive and negative patients, opposed to the reviews,
265 which reported only on positive tested patients, were documented regarding leucocytes,
266 neutrophils, and hemoglobin (Table 5).

267 In conformity with other publications [11, 12, 17], leucocytes were lower in COVID-19 positive
268 than negative patients at the time of PCR testing, and so were neutrophils and lymphocytes;
269 while severe compared to mild forms of COVID-19 tend to have higher leucocytes and
270 neutrophils. As opposed to our findings, which showed a low ability of NLR to discriminate
271 between positive and negative (AUC=0.561) and basically no contribution in the multivariate
272 analysis, a raised NLR, which evolved from a raised neutrophil count as well as a lowered
273 lymphocyte count, was already shown previously to be a prognostic value for endotracheal
274 intubation and mortality predictor.[13, 14] A cut-off of 4.94 was used in the publication by
275 Tatum et al. [14]; above this value, the risk of being artificially ventilated or to die was
276 increased. Notably, 89% of those patients were African Americans. A lower cut-off (2.33) was

277 established in our study, which might be because only 15% of patients had a neutrophil count
278 higher than $7.7 \times 10^9/L$. We are however unaware of any study using NLR as a pure discriminator
279 between positive and negative COVID-19 diagnosis.

280 However, severity of illness appears to be less important regarding the other parameters,
281 especially regarding eosinophils and CRP (Table 5). Like in other publications [12, 17], our data
282 also showed that eosinopenia was one of the significant predictive biomarkers for COVID-19
283 with a sensitivity of 85% and a specificity of 50%.

284 Li et al. [12] and our study showed an increased hemoglobin in COVID-19 positive patients,
285 which is not in accordance with a lowered hemoglobin in patients with severe COVID-19
286 disease reported by two meta-analyses.[8, 16] In our data, the median hemoglobin was 13.5
287 g/dL, which did not much differ from Li's data.[12] In several other trials assessing the severity
288 of disease and blood patterns, hemoglobin was shown to be below normal ranges.[8, 9, 16] It can
289 only be hypothesized why our cohort presented with a comparably high level of hemoglobin.
290 Possibly, a degree of dehydration played a role at the time of presentation in the emergency
291 department. Indeed, an average temperature of $38.0 \pm 0.9^\circ\text{C}$ on presentation in 99 COVID-19
292 positive and $37.1 \pm 1.4^\circ\text{C}$ in 103 COVID-19 negative patients, which was a significant difference,
293 was detected in a subgroup analysis of 202 of our patients.

294 Not surprisingly, CRP was significantly elevated in all studies.[11, 12, 17] In our patients, we set
295 a new cut-off using the Youden index of 22 mg/dL, since the vast majority of patients had
296 increased CRP values.

297 Similar blood patterns were also detected regarding ALT, AST, and LDH.[8, 9, 12, 16, 17]

298 Brinati et al. included 279 patients and developed a score for SARS-Cov-2 detection with an
299 accuracy between 82% and 86%, and sensitivity between 92% and 95%.[18] Applying our data
300 including age, gender, leucocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils,
301 thrombocytes, CRP, AST, ALT, GGT, and LDH to Brinati's tool, a quite high AUC
302 (AUC=0.709, 95%CI 0.646-0.771; $p < 0.001$), sensitivity (70.4%), specificity (71.3%), and NPV

303 (79.9%), but less promising PPV (59.8 %) could be obtained. However, our model including 14
304 standard laboratory blood parameters reached better diagnostic performances in all areas
305 (AUC=0.915, 95%CI 0.876-0.955); sensitivity (78.4%); specificity (87.3%), PPV (79.5%), and
306 NNP (86.6%)), although, the most prominent parameters were leucocytes, eosinophils,
307 hemoglobin, and CRP.

308 The following limitations of the study should be noted. The retrospective design with missing
309 blood parameters and no validation cohort are amongst the major limiting factors and thus, our
310 selected model may be over-fitted. Additionally, with the single time point evaluation, we were
311 not able to retrieve information regarding progression of the disease. Furthermore, cytokines,
312 especially interleukin-6, were not routinely measured, which may be better predictors, especially
313 regarding the so-called ‘COVID-19 cytokine storm’, to elucidate COVID-19 positive from
314 negative patients. Another fact to consider is the heterogeneity of underlying diseases, which
315 may also contribute to variations in our findings. On the other hand, such a heterogeneity may
316 reflect reality during a pandemic situation best. Eventually, all test quality crucially depends on
317 the quality of the manual specimen acquisition.[19, 20] PCR results tend to be more positive in
318 patients with an increased viral load and with a shorter duration of the disease.[21]

319 **Conclusions**

320 Generally, as laboratory equipment supply develops, more PCR point-of-care diagnostics
321 become available. It is nonetheless doubtful that - neither in the near, nor in the far future – PCR
322 will entirely replace standard laboratory testing. Therefore, the question of a blood laboratory
323 pattern, as specific as possible for COVID-19, remains relevant. Our multivariate model
324 including 14 standard blood parameters correctly classified 84% of cases with a sensitivity of
325 78% and a specificity of 87%, and therefore could be a useful model to facilitate rapid triage of
326 potential COVID-19 patients.

327

328 **Funding**

329 There was no acquisition of any funding for this trial.

330

331 **Acknowledgment**

332 All authors declare that they have no conflict of interest.

333

334 REFERENCES

- 335 1. Wang LF, Anderson DE, Mackenzie JS, Merson MH. From Hendra to Wuhan: what has
336 been learned in responding to emerging zoonotic viruses. *Lancet* **2020**; 395(10224): e33-
337 e4.
- 338 2. Wang Y, Kang H, Liu X, Tong Z. Combination of RT-qPCR testing and clinical features
339 for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. *J Med*
340 *Virol* **2020**; 92(6): 538-9.
- 341 3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases
342 of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*
343 **2020**; 395(10223): 507-13.
- 344 4. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
345 China. *N Engl J Med* **2020**; 382(18): 1708-20.
- 346 5. Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. *N Engl J Med* **2020**.
- 347 6. Mattiuzzi C, Lippi G. Which lessons shall we learn from the 2019 novel coronavirus
348 outbreak? *Ann Transl Med* **2020**; 8(3): 48.
- 349 7. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics
350 and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan,
351 China: a retrospective analysis. *Respir Res* **2020**; 21(1): 74.
- 352 8. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical
353 and immune biomarker abnormalities associated with severe illness and mortality in
354 coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin Chem Lab Med* **2020**;
355 58(7): 1021-8.
- 356 9. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with
357 COVID-19 disease progression. *Crit Rev Clin Lab Sci* **2020**: 1-11.
- 358 10. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With
359 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* **2020**.

- 360 11. Mardani R, Ahmadi Vasmehjani A, Zali F, et al. Laboratory Parameters in Detection of
361 COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study. Arch Acad
362 Emerg Med **2020**; 8(1): e43.
- 363 12. Li Q, Ding X, Xia G, et al. Eosinopenia and elevated C-reactive protein facilitate triage
364 of COVID-19 patients in fever clinic: a retrospective case-control study.
365 EClinicalMedicine **2020**: 100375.
- 366 13. Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor
367 for mortality in hospitalized patients with COVID-19. J Infect **2020**; 81(1): e6-e12.
- 368 14. Tatum D, Taghavi S, Houghton A, Stover J, Toraih E, Duchesne J. Neutrophil-to-
369 Lymphocyte Ratio and Outcomes in Louisiana Covid-19 Patients. Shock **2020**.
- 370 15. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection.
371 Clin Chem Lab Med **2020**; 58(7): 1131-4.
- 372 16. Alnor A, Sandberg MB, Gils C, Vinholt PJ. Laboratory tests and outcome for patients
373 with COVID-19: A systematic review and meta-analysis. J Appl Lab Med **2020**.
- 374 17. Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential
375 diagnostic tool for COVID-19. Clin Chem Lab Med **2020**; 58(7): 1095-9.
- 376 18. Brinati D, Campagner A, Ferrari D, Locatelli M, Banfi G, Cabitza F. Detection of
377 COVID-19 Infection from Routine Blood Exams with Machine Learning: A Feasibility
378 Study. J Med Syst **2020**; 44(8): 135.
- 379 19. Tu YP, Jennings R, Hart B, et al. Swabs Collected by Patients or Health Care Workers
380 for SARS-CoV-2 Testing. N Engl J Med **2020**; 383(5): 494-6.
- 381 20. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical
382 Specimens. JAMA **2020**.
- 383 21. Gorzer I, Buchta C, Chiba P, et al. First results of a national external quality assessment
384 scheme for the detection of SARS-CoV-2 genome sequences. J Clin Virol **2020**; 129:
385 104537.

386 **TABLES**

387

388 **Table 1. Comparison of Demographic Characteristics and 28-day Clinical Outcome**
 389 **between COVID-19 Positive and Negative tested Patients.**

Characteristic	COVID-19	COVID-19	P Value
	Positive (N=208)	Negative (N=382)	
Male – no./total no. (%)	117 (56.3)	197 (51.6)	0.276*
Age			
Median (IQR) - yr	72 (57-79.75)	70 (54-81)	0.526 [†]
Comorbidities – no./total no. (%)			
Hypertension	114 (54.8)	229 (59.9)	0.227*
Diabetes	50 (24.0)	100 (26.2)	0.569*
Coronary heart disease*	33 (15.9)	82 (21.5)	0.101*
Chronic lung disease [‡]	22 (10.6)	78 (20.4)	0.002*
Chronic kidney disease [‡]	29 (13.9)	64 (16.8)	0.371*
Malignant tumor [§]	12 (5.8)	68 (17.8)	<0.001*
Cerebro vascular accident [¶]	13 (6.3)	31 (8.1)	0.410*
Chronic liver disease [□]	2 (1.0)	23 (6.0)	0.004*
Human immunodeficiency virus	0	3 (0.8)	0.556 [‡]
Clinical 28-day outcome – no. (%)			
Not hospitalized/outpatient	23 (11.1)	33 (8.6)	<0.001*
Discharged after ≤28 days hospitalization not requiring ICU support or ventilation	97 (46.6)	245 (64.1)	
Discharged after ≤28 days hospitalization requiring ICU support and/or ventilation	4 (1.9)	25 (6.5)	

still in hospital after day 28	31 (14.9)	44 (11.5)	
Died before day 28	53 (25.5)	35 (9.2)	

390 Abbreviation: COVID-19, coronavirus disease 2019; ICU, intensive care unit; IQR, interquartile range

391 * Chi-square test; † Mann-Whitney U-test; ‡ Fischer's exact test

392

393

394 **Table 2. Comparison of Standard Blood Laboratory Parameters between COVID-19 Positive**
 395 **and Negative tested Patients.**

Parameters	N*	COVID-19 Positive	N*	COVID-19 Negative	P Value
<i>Blood count</i>					
Leucocytes ($10^9/L$)					
Median (IQR)	207	6.13 (4.80-8.08)	378	9.06 (6.59-12.45)	<0.001 [†]
Distribution – no./total no. (%)					
Low +normal (≤ 10.0)	179	86.5	221	58.5	<0.001 [‡]
High (>10.0)	28	13.5	157	41.5	
Neutrophil-to-lymphocyte ratio					
Median (IQR)	534	5.00 (2.83-8.10)		5.44 (3.30-9.25)	0.032 [†]
Distribution – no./total no. (%)					
≤ 2.33	36	19.8	27	7.7	<0.001 [‡]
>2.33	146	80.2	325	92.3	
Basophils ($10^9/L$)					
Median (IQR)	182	0.02 (0.01-0.03)	352	0.03 (0.02-0.04)	<0.001 [†]
Eosinophils ($10^9/L$)					
Median (IQR)	182	0.01 (0.00-0.05)	352	0.10 (0.04-0.20)	<0.001 [†]
Distribution – no./total no. (%)					
Low (<0.1)	155	85.2	176	50.0	<0.001 [‡]
Normal + high (≥ 0.1)	27	14.8	176	50.0	
Monocytes ($10^9/L$)					
Median (IQR)	182	0.47 (0.30-0.64)	352	0.56 (0.40-0.77)	<0.001 [†]
Distribution – no./total no. (%)					
Low + normal (≤ 0.9)	169	92.9	299	84.9	0.008 [‡]
High (>0.9)	13	7.1	53	15.1	
Thrombocytes ($10^9/L$)					
Median (IQR)	207	201 (161-252)	377	227 (169.5-299)	0.002 [†]
Hemoglobin (g/dL)					

Median (IQR)	207	13.50 (12.30-14.70)	378	11.75 (10.28-13.33)	<0.001 [†]
Distribution – no./total no. (%)					
Low (f: <11.8; m: <13.5)	67	32.4	234	61.9	<0.001 [†]
Normal + high (f: ≥11.8; m: ≥13.5)	140	67.6	144	38.1	
<i>Inflammation</i>					
C-reactive protein (mg/dL)					
Median (IQR)	205	61.80 (25.45-129.50)	381	33.60 (7.25-93.56)	<0.001 [†]
Distribution – no./total no. (%)					
<22 mg/dL	44	21.5	161	42.3	<0.001 [†]
≥22 mg/dL	161	78.5	220	57.7	
<i>Coagulation</i>					
Activated partial thromboplastin time (sec)					
Median (IQR)	141	29.90 (27.00-33.05)	298	27.00 (24.00-31.00)	<0.001 [†]
<i>Heart function</i>					
Creatine Kinase (U/L)					
Median (IQR)	181	127.0 (63.0-243.5)	336	102.5 (50.0-216.0)	0.023 [†]
Distribution – no./total no. (%)					
Normal (≤190)	113	62.4	246	73.2	0.011 [‡]
High (>190)	68	37.4	90	26.8	
Lactate dehydrogenase (U/L)					
Median (IQR)	157	285.0 (228.0-384.5)	294	225.0 (189.0-297.75)	<0.001 [†]
Distribution – no./total no. (%)					
Normal (≤250)	55	35.0	173	58.8	<0.001 [‡]
High (>250)	102	65.0	121	41.2	

396 Abbreviations: f, female; IQR, interquartile range; L, liter; m, male.

397 * Number of parameters available. [†] Mann-Whitney U-test [‡] Chi-square test [§] Fisher's exact test

398

399 **Table 2 (continued). Comparison of Standard Blood Laboratory Parameters between**
 400 **COVID-19 Positive and Negative tested Patients.**

Parameters	N*	COVID-19 Positive	N*	COVID-19 Negative	P Value
<i>Liver function</i>					
Alanine aminotransferase (U/L)					
Median (IQR)	171	32.00 (21.00-53.00)	346	25.00 (15.00-45.00)	0.001 [†]
Distribution – no./total no. (%)					
Normal (≤45)	111	64.9	261	75.4	0.012 [‡]
High (>45)	60	35.1	85	24.6	
Aspartate aminotransferase (U/L)					
Median (IQR)	124	47.00 (29.00-70.00)	205	26.00 (20.00-52.00)	<0.001 [†]
Distribution – no./total no. (%)					
Normal (≤35)	46	37.1	130	63.4	<0.001 [‡]
High (>35)	78	62.9	75	36.6	
Lipase (U/L)					
Median (IQR)	151	39.00 (25.00-65.00)	282	23.00 (14.00-41.00)	<0.001 [†]
Distribution – no./total no. (%)					
Normal (≤60.0)	106	70.2	240	85.1	<0.001 [‡]
High (>60.0)	45	29.8	42	14.9	
<i>Renal function</i>					
Creatinine (mg/dL)					
Distribution – no./total no. (%)					
Low (<0.5)	0	0	12	3.2	0.009 [‡]
Normal + high (≥0.5)	208	100.0	365	96.8	

401 Abbreviations: f, female; IQR, interquartile range; L, liter; m, male.

402 * Number of parameters available. [†] Mann-Whitney U-test [‡] Chi-square test [§] Fisher's exact test

403

404

405

406 **Table 3. Uni- and Multivariate Analyses of Standard Blood Laboratory Parameters with COVID-**
 407 **19 Positive tested Patients as the Dependent Variable.**

Parameters	Univariate OR (95% CI)	P Value	Multivariate OR (95% CI)	P Value
<i>Blood count</i>				
Leukocytes (10 ⁹ /L)	0.81 (0.77-0.86)	<0.001	0.69 (0.58-0.83)	<0.001
Leukocytes (ref: >10.0)	1.00			
leukopenia+normal (≤10.0)	4.54 (2.90-7.11)	<0.001	-	-
Neutrophil-to-lymphocyte ratio	1.00 (0.98-1.02)	0.745	-	-
Neutrophil-to-lymphocyte ratio (ref: >2.33)	1.00			
≤2.33	2.97 (1.74-5.07)	<0.001	1.72 (0.45-6.58)	0.428
Basophils (10 ⁹ /L)	9.55*10 ⁻¹⁸ (6.02*10 ⁻²³ -1.51*10 ⁻¹²)	<0.001	0.00 (0.00-1334.76)	0.133
Eosinophils (10 ⁹ /L)	0.00005 (0.000003-0.001)	<0.001	0.00 (0.00-0.97)	0.011
Eosinophils (ref: ≥0.1)	1.00			
eosinopenia (<0.1)	5.74 (3.63-9.09)	<0.001	-	-
Monocytes (10 ⁹ /L)	0.26 (0.13-0.51)	<0.001	0.93 (0.12-7.06)	0.942
Monocytes (ref: >0.9)	1.00			
monocytopenia+normal (≤0.9)	2.30(1.22-4.35)	0.010	-	-
Thrombocytes (10 ⁹ /L)	0.998 (0.997-1.00)	0.013	1.00 (1.00-1.01)	0.272
Thrombocytes (>370)	1.00			
thrombopenia+normal (≤370)	2.00 (1.10-3.66)	0.024	-	-
Hemoglobin (g/dL)	1.39 (1.27-1.52)	<0.001	1.63 (1.29-2.07)	<0.001
Hemoglobin (ref: f: <11.8; m: <13.5)	1.00			
normal+high (f: ≥11.8; m: ≥13.5)	3.40 (2.38-4.86)	<0.001	-	-
<i>Inflammation</i>				
C-reactive protein (U/L)	1.004 (1.002-1.006)	<0.001	1.01 (1.00-1.02)	0.025
C-reactive protein (ref: <22 mg/dL)	1.00			
≥22 mg/dL	2.68 (1.81-3.96)	<0.001	-	-

<i>Coagulation</i>				
Activated partial thromboplastin time (sec)	1.04 (1.01-1.08)	0.005	0.99 (0.92-1.06)	0.683
<i>Heart function</i>				
Creatine Kinase (U/L)	1.00004 (0.9999-1.0002)	0.675	-	-
Creatine kinase (ref: ≤190)	1.00			
high (>190)	1.65 (1.12-2.42)	0.011	0.84 (0.28-2.59)	0.767
Lactate dehydrogenase (U/L)	1.0005 (0.9996-1.001)	0.274	-	-
Lactate dehydrogenase (ref: ≤250)	1.00			
high (>250)	2.65 (1.77-3.96)	<0.001	2.36 (0.71-7.83)	0.159
<i>Liver function</i>				
Alanine aminotransferase (U/L)	0.999 (0.997-1.002)	0.519	-	-
Alanine aminotransferase (ref: ≤45)	1.00			
high (>45)	1.66 (1.12-2.47)	0.013	1.65 (0.55-4.96)	0.375
Aspartate aminotransferase (U/L)	1.000 (0.998-1.001)	0.653	-	-
Aspartate aminotransferase (ref: ≤35)	1.00			
high (>35)	2.94 (1.85-4.67)	<0.001	1.39 (0.44-4.38)	0.573
Lipase (U/L)	1.002 (0.999-1.005)	0.137	-	-
Lipase (ref: ≤60)	1.00			
high (>60)	2.43 (1.50-3.92)	<0.001	1.44 (0.42-4.97)	0.565
<i>Renal function</i>				
Creatinine (ref: 0.5-1.2mg/dL)	1.00		-	-
low (<0.5)	0.00	0.999		
high (>1.2)	1.26 (0.87-1.82)	0.214		

408 Abbreviation: CI, confidence interval; OR, odds ratio.

409

410 **Table 4 Diagnostic Performance of Single Standard Blood Laboratory Parameters to Distinguish**
 411 **Between COVID-19 Positive from Negative Tested Patients.**

Parameters	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	AUC (95% CI)	P value
Leukocytes (≤10.0 10 ⁹ /L)	86.5	41.5	44.8	84.9	0.640 (0.595-0.685)	<0.001
NLR (≤2.33)	19.8	92.3	57.1	69.0	0.561 (0.508-0.613)	0.022
Eosinophils (<0.10 10 ⁹ /L)	85.2	50.0	46.8	86.7	0.676 (0.630-0.722)	<0.001
Monocytes (≤0.9 10 ⁹ /L)	92.9	15.1	36.1	80.3	0.540 (0.489-0.590)	0.134
Thrombocytes (≤370 10 ⁹ /L)	92.8	13.5	37.1	77.3	0.209 (0.483-0.580)	0.209
Hemoglobin (f: ≥11.8; m: ≥13.5 g/dL)	67.6	61.9	49.3	77.7	0.648 (0.601-0.694)	<0.001
CRP (≥22 mg/dL)	78.5	42.3	42.3	78.5	0.604 (0.557-0.651)	<0.001
CK (>190 U/L)	37.6	73.2	43.0	68.5	0.554 (0.501-0.606)	0.043
LDH (>250 U/L)	65.0	58.8	45.7	75.9	0.619 (0.565-0.673)	<0.001
ALT (>45 U/L)	35.1	75.4	41.4	70.2	0.553 (0.499-0.606)	0.051
AST (>35 U/L)	62.9	63.4	51.0	73.9	0.632 (0.569-0.694)	<0.001
Lipase (>60 U/L)	29.8	85.1	51.7	69.4	0.575 (0.517-0.632)	0.011

412 Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; CRP, C-reactive protein;

413 LDH, lactate dehydrogenase; NLR, Neutrophil-to-lymphocyte ratio.

414 **Table 5. Blood parameter patterns of COVID-19 positive tested patients of various studies.**

	Present study	COVID-19	positive COVID-19
	COVID-19 positive	positive	severe
Leucocytes	↓	↓ [11, 12, 17]	↑ [8, 9, 16]
Neutrophils	↓	↓ [11, 12, 17]	↑ [8, 9, 16]
Lymphocytes	↓	↓ [11, 12, 17]	↓ [8, 9, 16]
Eosinophils	↓	↓ [12, 17]	↓ [8, 9]
Thrombocytes	↓	↓ [12]; not sig. ↓ [17]	↓ [8, 9, 16]
Hemoglobin	↑	not sig. ↑ [12]	↓ [8, 16]
CRP	↑	↑ [11, 12, 17]	↑ [8, 9, 16]
ALT	↑	↑ [12, 17]	↑ [8, 9]
AST	↑	↑ [12, 17]	↑ [8, 9, 16]
LDH	↑	↑ [12, 17]	↑ [8, 9, 16]

415 Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; LDH,
 416 lactate dehydrogenase.


417

418

419

FIGURE and figure legend

420



421

422 **Figure 1.** Receiver operating characteristic (ROC) curve of (A) the model with and area under the ROC
423 curve (AUC) of 0.915 (95% confidence intervals (CI), 0.876 to 0.955) and (B) the combined blood
424 parameters leucocytes (dotted grey line; AUC=0.278, 95%CI, 0.232 to 0.324), eosinophils (straight black
425 line; AUC=0.208, 95%CI, 0.165 to 0.250), hemoglobin (straight grey line; AUC=0.693, 95%CI, 0.646 to
426 0.739), and CRP (dotted black line; AUC=0.605, 95%CI, 0.555 to 0.655).

427

428